Sponsored Links
| BioCryst Announces Peramivir Phase 3 Safety & Virology Study Results And Provides A Clinical Program Update |
 |
 |
 |
| Medical News - Infectious Diseases and Viruses | |||
|
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced top-line results from one of its two Phase 3 studies of intravenous (i.v.) peramivir for the treatment of patients hospitalized with influenza, and provided an update regarding its peramivir program... Read more: Infectious Diseases / Bacteria / Viruses News From Medical News Today
|